TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis C$12.58 -0.17 (-1.33%) As of 04/1/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Cipher Pharmaceuticals Stock (TSE:CPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$12.53▼C$13.0050-Day RangeC$10.92▼C$14.1252-Week RangeC$7.97▼C$19.69Volume25,405 shsAverage Volume35,653 shsMarket CapitalizationC$225.85 millionP/E Ratio13.89Dividend YieldN/APrice TargetC$17.00Consensus RatingBuy Company OverviewCipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.Read More… Remove Ads Cipher Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCPH MarketRank™: Cipher Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCipher Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCipher Pharmaceuticals has received no research coverage in the past 90 days.Read more about Cipher Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cipher Pharmaceuticals is 13.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.55.Price to Earnings Ratio vs. SectorThe P/E ratio of Cipher Pharmaceuticals is 13.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.44.Price to Book Value per Share RatioCipher Pharmaceuticals has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCipher Pharmaceuticals does not currently pay a dividend.Dividend GrowthCipher Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CPH. News and Social Media2.8 / 5News Sentiment1.09 News SentimentCipher Pharmaceuticals has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cipher Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cipher Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$47,215.00 in company stock.Percentage Held by Insiders42.00% of the stock of Cipher Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.38% of the stock of Cipher Pharmaceuticals is held by institutions.Read more about Cipher Pharmaceuticals' insider trading history. Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPH Stock News HeadlinesCipher Pharmaceuticals Inc. (TSE:CPH) Director Sells C$47,215.00 in StockMarch 25, 2025 | insidertrades.comAnalysts Offer Predictions for TSE:CPH Q1 EarningsMarch 28, 2025 | americanbankingnews.comDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.April 2, 2025 | Altimetry (Ad)Leede Financial Weighs in on TSE:CPH FY2027 EarningsMarch 25, 2025 | americanbankingnews.comFY2025 EPS Estimates for TSE:CPH Decreased by AnalystMarch 23, 2025 | americanbankingnews.comEarnings call transcript: Cipher Pharmaceuticals Q4 2024 sees stock surgeMarch 21, 2025 | uk.investing.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 ResultsMarch 19, 2025 | theglobeandmail.comCipher Pharmaceuticals Inc.'s (TSE:CPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?March 17, 2025 | uk.finance.yahoo.comSee More Headlines CPH Stock Analysis - Frequently Asked Questions How have CPH shares performed this year? Cipher Pharmaceuticals' stock was trading at C$14.32 on January 1st, 2025. Since then, CPH stock has decreased by 12.2% and is now trading at C$12.58. View the best growth stocks for 2025 here. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) posted its quarterly earnings data on Thursday, August, 10th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.01. The company earned $7.10 million during the quarter, compared to analyst estimates of $7.46 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 17.93% and a net margin of 59.92%. How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Enbridge (ENB), Bellatrix Exploration (BXE), Crescent Point Energy (CPG), Manulife Financial (MFC), Surge Energy (SGY) and Toronto-Dominion Bank (TD). Company Calendar Last Earnings8/10/2023Today4/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$17.00 High Stock Price TargetC$17.00 Low Stock Price TargetC$17.00 Potential Upside/Downside+35.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C$0.91 Trailing P/E Ratio13.89 Forward P/E Ratio9.75 P/E GrowthN/ANet IncomeC$11.41 million Net Margins59.92% Pretax MarginN/A Return on Equity17.93% Return on Assets7.90% Debt Debt-to-Equity Ratio41.22 Current Ratio2.00 Quick Ratio2.67 Sales & Book Value Annual SalesC$19.03 million Price / Sales11.87 Cash FlowC$3.57 per share Price / Cash Flow3.53 Book ValueC$3.96 per share Price / Book3.18Miscellaneous Outstanding Shares17,953,309Free FloatN/AMarket CapC$225.85 million OptionableNot Optionable Beta1.20 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (TSE:CPH) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.